A prospective cohort examination of haematological parameters in relation to cancer death and incidence: The Busselton Health Study by Adris, N. et al.
RESEARCH ARTICLE Open Access
A prospective cohort examination of
haematological parameters in relation to
cancer death and incidence: the Busselton
Health Study
Niwansa Adris1, Anita Chai Geik Chua2,3, Matthew William Knuiman4, Mark Laurence Divitini4, Debbie Trinder2,3 and
John Kevin Olynyk1,5*
Abstract
Background: Cancer risk is associated with serum iron levels. The aim of this study was to evaluate whether
haematological parameters reflect serum iron levels and may also be associated with cancer risk.
Methods: We studied 1564 men and 1769 women who were enrolled in the Busselton Health Study, Western
Australia. Haematological parameters evaluated included haemoglobin (Hb), mean cell volume (MCV), mean cell
haemoglobin (MCH) and mean cell haemoglobin concentration (MCHC) and red cell distribution width (RCDW).
Statistical analyses included t-tests for quantitative variables, chi-square tests for categorical variables and Cox
proportional hazards regression modelling for cancer incidence and death.
Results: There was marginal evidence of an association between MCV (as a continuous variable) and non-skin
cancer incidence in women (HR 1.15, 95% CI 1.013, 1.302; p = 0.030) but the hazard ratio was attenuated to non-
significance after adjustment for serum ferritin (SF), iron and transferrin saturation (TS) (HR 1.11, 95% CI 0.972, 1.264;
p = 0.126). There was strong evidence of an association between MCHC and prostate cancer incidence in men; the
estimated hazard ratio for an increase of one SD (0.5) in MCHC was 1.27 (95% CI 1.064, 1.507; p = 0.008). These
results remained significant after further adjustment for SF and iron; the estimated hazard ratio for an increase of
one SD (0.5) in MCHC was 1.25 (p = 0.014, 95% CI 1.05 to 1.48).
Conclusions: The MCHC and MCV were associated with cancer incidence in a Western Australian population,
although only MCHC remained associated with prostate cancer after adjusting with serum iron and TS (circulating iron)
and SF (storage iron). Haematological parameters are thus of limited utility in population profiling for future cancer risk.
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Background
Iron is an essential micronutrient for human health as it
participates in a vast range of metabolic processes [1–4].
Deficiency or excess of iron have both been implicated as
vital pathogenic processes of various chronic diseases.
Iron deficiency is implicated in anaemia [5, 6], worsening
symptoms of chronic heart failure [7, 8] and restless leg
syndrome [9, 10]. On the other hand, iron excess as ob-
served in hereditary haemochromatosis and haemato-
logical disorders such as thalassaemia major and sickle
cell disease has been associated with liver cirrhosis, type
two diabetes mellitus and cardiomyopathy [11–20].
Recent studies have implicated iron in the pathogenesis
of cancer. In hereditary haemochromatosis an increased
risk of cancer with iron overload has been demonstrated
[21–24]. More recent population studies have shown even
at high physiological levels of iron, there was increased risk
of cancer [25–27]. On the contrary, depletion of iron has
been proposed to have a protective role on cancer
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development [28–35]. In our previous study of the Bussel-
ton population, we found that higher concentrations of
serum iron or TS were associated with an increased inci-
dence of non-skin cancer in women, increased risks of
breast cancer and of cancer death [25]. Thus iron status
may be useful in stratifying risk for cancer.
Iron is essential for erythropoiesis [36], and low serum iron
parameters may be reflected by changes in haematological
parameters such as a reduction in mean haemoglobin (Hb),
mean corpuscular volume (MCV), mean cell haemoglobin
(MCH), and mean corpuscular haemoglobin concentration
(MCHC) and an increase in red cell distribution width
(RCDW) [37, 38]. Conversely, several studies of individuals
with iron overload, such as in hereditary haemochromatosis,
have shown that elevation in iron stores was associated with
increased values of Hb, MCV, MCH, and MCHC [39–41].
The full blood count assay is a relatively cheap and
easily measured laboratory investigation that is con-
ducted worldwide. In Australia it is estimated that ap-
proximately 12 million full blood counts are ordered per
year [42]. Whilst serum iron biochemistry is also com-
monly performed, the full blood count is performed
more than twice as frequently as iron studies [42]. The
cost of the full blood count is approximately half the
cost of iron studies in Australia and elsewhere [43–45].
Given the positive association between iron levels and
cancer incidence and death from our previous study [25],
we aimed to assess the utility of haematological parame-
ters such as the Hb, RCDW, MCV, MCH and MCHC as
surrogate markers of iron bioavailability to determine the
associations between these parameters and cancer death
and incidence in the Busselton population.
Methods
Study population
Busselton is a city situated in the southwest of Western
Australia and more than 90% of its residents consist of indi-
viduals with Anglo-Celtic ancestry. The residents of this
coastal city have been regularly surveyed since the intro-
duction of the Busselton Health Study in 1966. A follow-up
health survey of survivors from surveys during 1966 to
1987 was performed in 1994 and 1995 [46, 47]. Inclusion
criteria for this study were individuals who participated in
the 1994/1995 survey aged 25–79 years and who had rele-
vant data, no history of cancer at the time of survey, not
taking haemopoietic agents and SF ≥20 μg/L. This study
was approved by the Busselton Population Medical Re-
search Institute and ethics approval was obtained from the
Human Research Ethics Committee of the Health Depart-
ment of Western Australia (Project number 2011/60).
Clinical and biochemical measurements
Participants of this survey completed a comprehensive
health and lifestyle questionnaire and were subject to
various measurements and tests [46]. Data on smoking, al-
cohol intake, menopausal status, use of iron supplements,
and history of blood donations was obtained from the
questionnaire. Alcohol use was classified as light, moder-
ate and heavy if intake was < 140 g/week, 140–420 g/week
and > 420 g/week, respectively. Trained assessors obtained
data on anthropometric measures such as waist circumfer-
ence, weight and height, from which body mass index
(BMI) was derived. Blood pressures were measured after
five minutes of rest in a seated position.
After an overnight fast at time of the survey, blood sam-
ples were collected from the participants. Their serum
was separated and stored at − 70 °C. Serum biochemical
measurements of haematological indices (Hb, MCV,
MCH, MCHC, RCDW), iron indices (iron, TS, SF), lipids
(high density lipoprotein (HDL) cholesterol, triglyceride),
glucose and insulin, liver function enzymes and proteins
(alanine transaminase (ALT), gamma-glutamyl transferase
(GGT), albumin, bilirubin) and a marker of inflammation
(C-reactive protein; C-RP) were performed using standard
protocols by PathWest Laboratories (Nedlands, Western
Australia). Using the following equation: (fasting insulin
(μIU/mL) x fasting glucose (mmol/L)) ÷ 22.5, the Homeo-
stasis Model Assessment-estimated insulin resistance
(HOMA-IR) score was calculated.
Cancer outcomes
By accessing the Death Register and Cancer Register from
the Western Australian Department of Health within the
time frame of January 1994 until June 2014, the incidence
of cancer and death records were collected [48]. Cancer var-
iables analysed included death from (non-skin) cancer
(ICD10 C00-C42, C45-C97), incident non-skin cancer
(ICD10 C00-C42, C45-C97), incident prostate cancer (men
only, ICD10 C61), incident breast cancer (women only,
ICD10 C50), and incident colorectal cancer (ICD10
C18-C21) where an incident case is a non-fatal or fatal case.
Statistical analyses
Statistical analyses were performed using SAS® 9.4. Log
transformation of data was performed for variables that
had positively skewed distributions (SF, iron and TS, triglyc-
erides, glucose, HOMA-IR, ALT, GGT, C-RP). Differences
in characteristics between men and women were examined
using t-tests for quantitative variables and chi-square tests
for categorical variables. The associations between haem-
atological parameters (Hb, MCV, MCH, MCHC and
RCDW) and cancer incidence and death were examined
using Cox proportional hazards regression modeling.
Haematological parameters were examined both as a con-
tinuous variable and in three gender-specific approximate
tertile categories. The estimated hazard ratios with 95%
confidence interval were reported for each of the haemato-
logical parameters in relation to cancer incidence and death
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in men and women based on cancer and mortality
follow-up to 30 June 2014. 95% confidence intervals for a
hazard ratio that do not include the value 1 are significant
at the 5% level (i.e. p < 0.05). All models were adjusted for
age, smoking, alcohol consumption, BMI, and waist cir-
cumference. Modelling of breast cancer risk in women was
also adjusted for menopausal status.
Results
A total of 1564 men and 1769 women met the study inclu-
sion criteria. Baseline demographic, anthropometric and bio-
chemical characteristics of the cohort, stratified according to
gender, are presented in Table 1. The study cohort com-
prised of 47% men, with a mean age of 51 ± 14 years, and
53% of women with a mean age of 52 ± 15 years. Approxi-
mately 57% of women were post-menopausal and a third of
these women used hormone replacement therapy. Oral con-
traceptives were used by 27% of pre-menopausal women.
More men were current smokers or ex-smokers and also
consumed more alcohol than women. A small proportion of
the Busselton cohort was taking iron supplements to treat
iron deficiency, 0.6% of men and 4.7% of women respect-
ively, and about a third of men and women reported a his-
tory of blood donation. Hb and MCHC were significantly
higher in men (p < 0.001) whereas MCV, MCH and RCDW
were similar in men and women. SF, iron and TS levels were
higher in men than in women (p < 0.001) and had positively
skewed distributions. With the exception of HDL choles-
terol and C-RP levels, all the other measured variables were
also higher in men than in women (p < 0.001).
A total of 202 cohort participants died from cancer during
the 20-year follow-up period and 191 were non-skin cancer
deaths. A total of 588 participants had an incident non-skin
cancer. A greater proportion of men developed non-skin
cancer compared to women (19.4% in men versus 16.1% in
women) whilst a similar proportion of non-skin cancer
deaths and incident colorectal cancers were recorded for
both men and women during the follow-up period. Of the
sex-specific cancers, the proportion of men who were diag-
nosed with prostate cancer and women who were diagnosed
with breast cancer was 8.2% and 5.2%, respectively.
Table 2 shows the correlations between haematological
parameters and iron parameters. Hb was weakly correlated
with MCV and moderately positively correlated with MCH
and MCHC (0.04 to 0.14). MCV and MCH were very
strongly positively correlated (0.93 in men and women),
however MCV was not correlated with MCHC whereas
MCH was positively correlated with MCHC (0.30 in men
and 0.36 in women). RCDW was weakly to moderately
negatively correlated with Hb, MCV, MCH, and MCHC.
Hb was positively correlated with SF, iron and TS in
both men and women (0.09 to 0.16). MCV and MCH
showed stronger correlations with iron and TS (0.20 to
0.31) than with SF (0.08 to 0.10) in men and women.
MCHC showed weak correlations with SF, iron and TS
(− 0.02 to 0.12) in men and women. RCDW showed
negative correlations with SF, iron and TS (− 0.12 to −
0.14) in men and negative correlations with iron and TS
(− 0.16 to − 0.17) but not with SF (0.03) in women.
Estimated hazard ratios for Hb, MCV, MCH, MCHC,
and RCDW both as continuous variables and in approxi-
mate tertile groups, in relation to cancer incidence and
death after adjustment for cancer risk were determined.
There were only two instances of possible associations
between a haematological parameter and cancer inci-
dence in men or women. There was marginal evidence
of an association between MCV (as a continuous vari-
able) and non-skin cancer incidence in women (hazard
ratio 1.15, 95% CI 1.013, 1.302; p = 0.030) but the hazard
ratio was attenuated to non-significance after adjustment
for SF, iron and TS (hazard ratio 1.11, 95% CI 0.972,
1.264; p = 0.126). There was strong evidence of an asso-
ciation between MCHC and prostate cancer incidence in
men; the estimated hazard ratio for an increase of one
SD (0.5) in MCHC was 1.27 (95% CI 1.064, 1.507; p =
0.008). Men with a MCHC ≤34.1 g/100 ml had a signifi-
cantly lower risk of prostate cancer compared with men
who had a MCHC above this value. Further, these asso-
ciations remain after further adjustment for SF, iron and
TS with the estimated hazard ratio for an increase of
one SD (0.5) in MCHC being 1.25 (p = 0.014, 95% confi-
dence interval 1.05 to 1.48).
Haematological parameters did not exhibit any associ-
ation with incidence or death for breast cancer in women
or colorectal cancer in women or men. Blood donation
was not associated with cancer incidence and death.
Discussion
To the best of our knowledge, this is the first large-scale
population study to investigate the prospective association
between haematological parameters as surrogate markers
of iron bioavailability, and cancer incidence and death.
In this prospective, observational cohort study, we ob-
served a strong association between MCHC and prostate
cancer incidence that remained significant following ad-
justments for iron markers. There was also a marginal as-
sociation between MCV and non-skin cancer incidence in
women which was attenuated to non-significance after ad-
justment for iron markers. Hb, MCH and RCDW did not
generate any significant association with cancer incidence
or death.
We postulate that the overall weak correlation between
haematological parameters and serum iron markers in
our study may be attributed to the fact that changes in
iron levels are reflected to some degree through red blood
cell morphology [36, 49, 50]. Factors that could confound
the association include diurnal variation in serum iron
levels [51–56] and unmeasured changes in iron and
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Table 1 Characteristics of the study cohort and number of cancers and cancer deaths by gender. Table shows mean (SD), percent
or number (percent) for cancer outcomes
Characteristic Men (n = 1564) Women (n = 1769) p-value
Hb (g/dL) 151.4 (9.6) 135.5 (8.7) < 0.001
MCV (fL) 89.0 (3.6) 89.1 (3.7) 0.225
MCH (pg/cell) 30.6 (1.3) 30.5 (1.4) 0.152
MCHC (g/dL) 34.4 (0.5) 34.3 (0.5) < 0.001
RCDW 0.13 (0.01) 0.13 (0.01) 0.014
SF (μg/L) 228 (211) 101 (105)
Log SF 5.17 (0.73) 4.33 (0.73) < 0.001
Serum iron (μmol/L) 19.0 (5.6) 17.9 (5.7)
Log serum iron 2.90 (0.30) 2.83 (0.33) < 0.001
TS (%) 30.2 (10.5) 27.0 (13.9)
Log TS 3.35 (0.34) 3.23 (0.36) < 0.001
Age (years) 50.7 (14.4) 51.9 (15.1) 0.022
Smoking status
Never 41.6 58.5 < 0.001
Ex 41.8 30.0
Current 16.6 11.6
Alcohol consumption Never 3.3 8.2 < 0.001
Ex 6.4 11.6
Light 48.5 67.2
Moderate/Heavy 39.1 8.6
Unknown 2.7 4.4
Menopausal status Pre/OC No – 31.4 –
Pre/OC Yes – 11.6
Post/HRT No – 38.4
Post/HRT Yes – 18.5
Use of iron supplement 0.6 4.7 < 0.001
History of blood donation 34.6 28.9 < 0.001
Body mass index (kg/m2) 26.7 (3.3) 25.9 (4.7) < 0.001
Waist circumference (cm) 93.6 (9.9) 81.2 (11.8) < 0.001
Systolic blood pressure (mm Hg) 127 (15) 122 (18) < 0.001
Diastolic blood pressure (mm Hg) 78 (10) 73 (10) < 0.001
High density lipoprotein chol (mmol/L) 1.21 (0.30) 1.54 (0.39) < 0.001
Triglycerides (mmol/L) 1.47 (1.06) 1.21 (0.75)
Log Triglycerides 0.21 (0.56) 0.05 (0.52) < 0.001
Glucose, mmol/L 5.13 (1.43) 4.90 (1.22)
Log Glucose 1.61 (0.18) 1.57 (0.17) < 0.001
HOMA-IR 1.90 (5.11) 1.67 (2.13)
log HOMA-IR 0.33 (0.68) 0.24 (0.65) < 0.001
ALT (IU/L) 28.2 (16.3) 19.3 (10.6)
Log ALT 3.23 (0.45) 2.86 (0.41) < 0.001
GGT (IU/L) 31.0 (23.8) 21.8 (17.2)
Log GGT 3.27 (0.53) 2.93 (0.50) < 0.001
Bilirubin (μmol/L) 11.2 (5.3) 9.0 (3.8) < 0.001
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haematological parameters in the timeframe between
entry into the study and endpoint determination. Several
studies have reported positive correlations between serum
iron or SF levels with TS, MCV and MCH [57, 58], whilst
others have shown no significant correlation between
MCV with TS and SF [59, 60].
This study demonstrates consistent trends in associations
between increasing iron or haematological parameters and
incidence for some cancers. Interestingly, the association
between MCHC and prostate cancer was independent of
adjustment for iron parameters whilst that of MCV and
non-skin cancer in women was dependent on iron. We hy-
pothesise that the variation in our findings can be attrib-
uted to the fact that even though iron may contribute to
cancer via induction of oxidative stress, changes in the red
blood cell parameters may also reflect changes to the body
as a result of long term oxidative stress that parallels the
drive for carcinogenesis [61–71]. The association between
MCHC and prostate cancer which remained significant
after iron studies adjustments leads us to speculate that
prostate carcinogenesis may be driven by alternative
oxidative stress mediators possibly independent of iron.
Although many studies have reported an association be-
tween oxidative stress and prostate cancer development, in-
consistent reports have emerged on the association
between iron and prostate carcinogenesis [72–79].
Whilst several studies have reported positive associa-
tions between MCHC and oral squamous cell carcinoma
[80] or head and neck cancers [81], others found no sta-
tistically significant associations [82, 83].
Inconsistent results have been reported regarding the as-
sociation between MCV and cancer. A retrospective Japa-
nese study found that elevated MCV was associated with
the presence of lymphoid and solid organ cancers [84]. In
contrast, a study of 253 patients with involuntary weight
loss who were investigated for cancer found that MCV was
not associated with cancer [85]. We observed an association
between MCV, as a continuous variable, and non-skin can-
cer incidence. A retrospective much larger Korean cohort
study of 36,260 cancer-free, non-anaemic men and women
found that elevated MCV by quartiles was related to higher
all-cause mortality and liver cancer mortality. There was a
Table 1 Characteristics of the study cohort and number of cancers and cancer deaths by gender. Table shows mean (SD), percent
or number (percent) for cancer outcomes (Continued)
Characteristic Men (n = 1564) Women (n = 1769) p-value
Albumin (g/L) 45.9 (2.7) 44.7 (2.6) < 0.001
C-RP (mg/L) 2.69 (7.30) 3.62 (10.08)
log C-RP 0.26 (1.18) 0.54 (1.22) < 0.001
Cancer outcomes
Non-skin cancer death 94 (6.0) 97 (5.5) 0.514
Non-skin cancer 304 (19.4) 284 (16.1) 0.011
Prostate cancer 129 (8.2) – –
Breast cancer – 92 (5.2) –
Colorectal cancer 42 (2.7) 46 (2.6) 0.878
OC (oral contraceptives), HRT (hormone replacement therapy), HOMA-IR (Homeostasis Model Assessment – estimated insulin resistance), ALT (alanine
transaminase), GGT (gamma-glutamyltransferase), C-RP (C-reactive protein)
Table 2 Correlations between haematological parameters and iron parameters in men and women
Hb MCV MCH MCHC RCDW Log SF Log iron Log TS
Men
Hb 1.000 −0.009 0.044 0.140 −0.111 0.127 0.156 0.088
MCV 1.000 0.930 −0.074 − 0.001 0.081 0.196 0.210
MCH 1.000 0.297 −0.110 0.118 0.216 0.223
MCHC 1.000 −0.298 0.112 0.077 0.061
RCDW 1.000 −0.123 −0.117 −0.135
Women
Hb 1.000 0.065 0.101 0.117 −0.072 0.134 0.152 0.110
MCV 1.000 0.934 0.007 −0.143 0.101 0.272 0.291
MCH 1.000 0.360 −0.249 0.088 0.291 0.314
MCHC 1.000 −0.332 −0.020 0.107 0.121
RCDW 1.000 0.028 −0.178 −0.164
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difference between genders with the highest quartile of
MCV (≥95.8 fL) showing higher cancer mortality in men
but not in women [86]. A retrospective study by Qu et al.
observed that a high MCHC and MCV level was an inde-
pendent prognostic factor for overall survival in non-small
cell lung cancer [87]. We speculate the association between
elevation of MCV and cancer in our study may be a conse-
quence of long-term effects of iron-dependent oxidative
stress on the red blood cell structure and cancer pathogen-
esis [86, 88]. This mechanism still remains ambiguous and
further research is needed to elucidate this hypothesis.
Substantial variability of findings has been observed in
studies that investigated the association between RCDW
and various cancers. A positive association have been re-
ported in colon cancer [61, 89] endometrial cancer [90]
oesophageal cancer [91–94] renal cell carcinoma [95] or
breast cancer [96–98], whilst other studies found no sta-
tistically significant associations [85, 99].
There are strengths and limitations of our study.
Strengths of our study include a well-defined,
community-based cohort with a long follow-up period
and adjustment of associations for a wide range of poten-
tial confounders. We excluded patients who were using
erythropoeisis-stimulating agents that can affect these
hematological parameters. Weaknesses include the rela-
tively limited cohort size, which may have limited power,
and the limited number of time-points during the course
of the follow-up. Furthermore, we tested five haemato-
logical parameters for five cancers in men and women
raising the possibility of false positive findings. Hence, the
significance of the discovered possible associations be-
tween MCV and non-skin cancer incidence in women (p
= 0.030) and MCHC and prostate cancer incidence in
men (p = 0.008) should be regarded with care. In the
current study, data on potential confounders for specific
cancer risk factors, such as intake of red meat, fish, fibre,
saturated fat and vitamin and mineral levels were unavail-
able and thus may also contribute to the inconsistent find-
ing with those of previously published studies. As study
subjects self-reported their histories of smoking and alco-
hol use during their participation in the survey, this may
also limit accuracy of data. The nature of any patho-
physiological process effecting haematological parameters
decades before the occurrence of cancer and which con-
tributes to cancer development remains unclear.
Conclusions
In conclusion, both MCHC and MCV were associated
with cancer incidence in a Western Australian popula-
tion, although only MCHC remained associated with
prostate cancer incidence after adjusting with serum
iron and TS (circulating iron) and SF (storage iron).
Haematological parameters are thus of limited utility in
population profiling for future cancer risk.
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